18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-...
Background Vepdegestrant (ARV-471) is an oral proteolysis-targeting chimeras (PROTAC) estrogen receptor (ER) degrader. In a phase 1/2 study (NCT04072952), vepdegestrant monotherapy had a favorable safety profile and encouraging clinical activity with …